Venous Thromboembolism Prophylaxis in Gynecologic Surgery A Systematic Review

Department of Obstetrics & Gynecology, Division of Female Pelvic Medicine & Reconstructive Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9032, USA.
Obstetrics and Gynecology (Impact Factor: 4.37). 11/2011; 118(5):1111-25. DOI: 10.1097/AOG.0b013e318232a394
Source: PubMed

ABSTRACT To comprehensively review and critically assess the available gynecologic surgery venous thromboembolism prophylaxis literature and provide clinical practice guidelines.
MEDLINE and Cochrane databases from inception to July 2010. We included randomized controlled trials in gynecologic surgery populations. Interventions and comparators included graduated compression stockings, intermittent pneumatic compression, unfractionated heparin, and low molecular weight heparin; placebo and routine postoperative care were allowed as comparators.
One thousand two hundred sixty-six articles were screened, and 14 randomized controlled trials (five benign gynecologic, nine gynecologic oncology) met eligibility criteria. In addition, nine prospective or retrospective studies with at least 150 women were identified and provided data on venous thromboembolism risk stratification, gynecologic laparoscopy, and urogynecologic populations.
Two reviewers independently screened articles with discrepancies adjudicated by a third. Eligible randomized controlled trials were extracted for these characteristics: study, participant, surgery, intervention, comparator, and outcomes data, including venous thromboembolism incidence and bleeding complications. Studies were individually and collectively assessed for methodologic quality and strength of evidence. Overall incidence of clinical venous thromboembolism was 0-2% in the benign gynecologic population. With use of intermittent pneumatic compression for benign major procedures, venous thromboembolism incidence was less than 1%. No venous thromboembolisms were identified in prospective studies of benign laparoscopic procedures. Overall quality of evidence in the benign gynecologic literature was poor. Gynecologic-oncology randomized controlled trials reported venous thromboembolism incidence (including "silent" venous thromboembolisms) of 0-14.8% with prophylaxis and up to 34.6% without prophylaxis. Fair quality of evidence supports that unfractionated heparin and intermittent pneumatic compression are both superior to placebo or no intervention but insufficient to determine whether heparins are superior to intermittent pneumatic compression for venous thromboembolism prevention. Combining two of three risks (aged 60 years or older, cancer, or personal venous thromboembolism history) substantially elevated the risk of venous thromboembolism.
Intermittent pneumatic compression provides sufficient prophylaxis for the majority of gynecology patients undergoing benign surgery. Additional risk factors warrant the use of combined mechanical and pharmacologic prophylaxis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this review is 1) to analyze the literature describing the benefits of minimally invasive gynecologic surgery in obese women, 2) to review the physiologic considerations associated with obesity, and 3) to describe surgical techniques that will enable surgeons to perform laparoscopy and robotic surgery successfully in obese patients. A Medline search of all English language articles published between 1993-2013 containing the search terms "laparoscopy", "obesity", "robotic surgery", "minimally invasive surgery and obesity" and "gynecologic laparoscopy" was performed. Obesity is on the rise in the United States, and the incidence of morbid obesity is especially growing in women. Obesity is associated with a vast range of co-morbid conditions that may impact perioperative outcomes, including hypertension, atherosclerosis, angina, obstructive sleep apnea, and diabetes mellitus. Obese patients who undergo laparoscopy or robotic surgery have shorter hospital stays, less postoperative pain, and fewer wound complications when compared with obese patients who undergo a laparotomy. Specific intra-abdominal access and trocar positioning techniques as well as anesthetic maneuvers improve the likelihood of success with laparoscopy in women with central adiposity. Performing gynecologic laparoscopy in the morbidly obese is no longer a rare event. Increases in the heaviest weight categories involve changes in clinical practice patterns. With comprehensive, thoughtful preoperative and surgical planning, minimally invasive surgery may be performed safely-and is of particular benefit-in the obese gynecologic surgery patient.
    Journal of Minimally Invasive Gynecology 10/2013; 21(2). DOI:10.1016/j.jmig.2013.09.009 · 1.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Risk of pelvic floor disorders increases after menopause and may be linked to estrogen deficiency. We aimed to systematically and critically assess the literature on vaginal estrogen in the management of pelvic floor disorders in postmenopausal women and provide evidence-based clinical practice guidelines. MEDLINE and Cochrane databases were searched from inception to July 2014 for randomized controlled trials of commercially available vaginal estrogen products compared with placebo, no treatment, or any medication for overactive bladder or urinary incontinence. We double-screened 1,805 abstracts and identified 12 eligible papers. Studies were extracted for participant information, intervention, comparator, efficacy outcomes, and adverse events, and they were individually and collectively assessed for methodological quality and strength of evidence. Evidence was generally of poor to moderate quality. Vaginal estrogen application before pelvic organ prolapse surgery improved the vaginal maturation index and increased vaginal epithelial thickness. Postoperative vaginal estrogen use after a midurethral sling resulted in decreased urinary frequency and urgency. Vaginal estrogen and immediate-release oxybutynin were similar in improvement of urinary urgency, frequency, and urgency urinary incontinence in women with overactive bladder, but oxybutynin had higher rates of side effects and discontinuation. Conversely, the addition of vaginal estrogen to immediate or extended-release tolterodine did not improve urinary symptoms more than tolterodine alone. One study reported an improvement in stress urinary incontinence with use of vaginal estrogen. Vaginal estrogen application may play a useful role as an adjunct in the management of common pelvic floor disorders in postmenopausal women.
    International Urogynecology Journal 11/2014; 26(1). DOI:10.1007/s00192-014-2554-z · 2.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives. Current recommendations for the use of venous thromboprophylaxis in patients undergoing minimally invasive surgery (MIS) for a gynecologic malignancy are derived from patients undergoing open surgery. Our objective was to determine the 30-day prevalence of symptomatic venous thromboembolism (VTE) after laparoscopic gynecologic oncology procedures in patients who received no thromboprophylaxis. Methods. Between January 2006 and September 2013, women who underwent MIS for endometrial, cervical or ovarian cancer at a single institution were included. Data on patient demographics, diagnosis, comorbidities, perioperative characteristics, use of thromboprophylaxis, and diagnosis of VTE were collected retrospectively. Results. Of the 419 patients who underwent MIS for a gynecologic cancer, 352 (84%) received no VIE prophylaxis. At least a total laparoscopic hysterectomy (simple or radical) or pelvic lymph node dissection was performed in 95% of these patients. The median length of surgery was 137 min and 95% of patients were discharged home within 1 day of surgery. The rate of VTE in the 352 untreated patients was 0.57% (1 pulmonary embolism and 1 deep vein thrombosis). There were no VIE diagnosed within 30 days of surgery in the 67 patients who received anticoagulant thromboprophylaxis. Conclusion. The rate of VIE is low in patients undergoing minimally invasive surgery for a gynecologic malignancy despite no VIE prophylaxis. The benefits of routine use of VIE prophylaxis in this population are questionable.
    Gynecologic Oncology 05/2014; 134(2). DOI:10.1016/j.ygyno.2014.05.012 · 3.69 Impact Factor

Full-text (2 Sources)

Available from
May 27, 2014